Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2016 Mar 21.
Published in final edited form as: Vet Pathol. 2011 Jul 6;49(4):629–635. doi: 10.1177/0300985811412619

Spontaneous Pulmonary Alveolar Proteinosis in Captive "Moustached Tamarins" (Saguinus mystax) (Primates: Callitrichidae)

Carmen R Michaud 1, Dan R Ragland 2,3, Katherine I Shea 1,4, Patricia M Zerfas 5, Robin J Kastenmayer 1, Marisa C St Claire 2, William R Elkins 1, Alfonso S Gozalo 1,4
PMCID: PMC4801348  NIHMSID: NIHMS763755  PMID: 21734058

Abstract

Pulmonary alveolar proteinosis (PAP) is a rare human disease characterized by accumulation of surfactant in alveoli without generating an inflammatory response. Lung lesions resembling PAP were observed in seven adult tamarins (five males and two females). Gross lesions were characterized by areas of discoloration, slight bulging over the lung parenchyma, and occasional consolidation. Histological examination of tamarin lung samples revealed intra-alveolar accumulation of an amorphous, amphophilic, PAS-positive, finely granular to dense material. In some cases type II pneumocyte hypertrophy and hyperplasia with pleural and septal thickening and fibrosis were observed. Large numbers of intra-alveolar foamy macrophages were noted surrounding and/or in the vicinity of the lesions. Immunohistochemical analysis of the lung lesions using polyclonal (surfactant proteins A, B, and C) and monoclonal (surfactant protein D) antibodies revealed the granular material to be composed largely of surfactant protein B, followed by surfactant protein A. Surfactant proteins C and D (SP-D) were present in lesser quantities; with SP-D observed surrounding the lipoproteinaceous deposits. Transmission electron microscopy of the affected lungs showed numerous, irregularly-shaped, osmiophilic lamellar bodies in type II pneumocytes. The cytoplasm in alveolar macrophages was expanded, containing ingested surfactant with swollen mitochondria and rough endoplasmic reticulum. Thoracic radiographs, available in one animal, depicted the lesions as small multifocal opacities randomly distributed in cranial and diaphragmatic lung lobes. This is, to our knowledge, the first report of spontaneous PAP in nonhuman primates.

Keywords: non-human primate, lung, surfactant proteins, immunohistochemistry, electron microscopy

Introduction

Pulmonary Alveolar Proteinosis (PAP), is an uncommon disorder in humans first described by Rosen et al., in 1958.19 PAP is characterized by the abnormal accumulation of surfactant in alveolar spaces without the presence of inflammatory cells,7,19,21,25 and the consequent interference with gas exchange. This eosinophilic, PAS-positive accumulation is due to impaired function of alveolar macrophages.3,7,12,19,21,25 The etiology of the disease appears to be multifactorial and has been classified in three forms: acquired, secondary, and congenital.3,7,21,25 The disease presentation varies from subclinical to respiratory failure and death. Spontaneous improvement with resolution may also occur.19,20,21,25

Treatment of PAP depends on the form. The current standard therapy for all forms is whole-lung lavage to remove the accumulated surfactant.3,13 Subcutaneous and nebulized administration of GM-CSF has proven useful in treating the idiopathic form.10,13 The secondary form is treated by removing the offending agent or the predisposing condition.13 The congenital form has a poor prognosis and is treated with supportive care or lung transplantation.13 Further reviews of current therapies and the molecular basis of PAP and surfactant homeostasis are available.3,10,12,13,18,25 Herein we report seven cases resembling PAP in "Moustached Tamarins" (Saguinus mystax).

Materials and Methods

Animals

Twenty-four adult Saguinus mystax died or were euthanized because of untoward clinical signs and/or poor response to treatment between February 24th 2006 and April 12th 2010, complete necropsies were performed. Clinical records and/or necropsy reports were not available for all animals. Of the 24 tamarins, 16 were males and eight females. Sixteen animals were wild-caught, five captive-born, and the remaining three had no data available. From these 24 animals, 15 were used in an Institutional Animal Care and Use Committee-approved viral hepatitis (hepatitis A virus and hepatitis GB virus type B) studies and nine were on an Institutional Animal Care and Use Committee-approved holding protocol (research-naïve).

Seven animals presented lesions compatible with PAP. Five were wild-caught (three males and two females, >8–10 years old), being one male and one female research-naïve; and two, a six year-old male set of twins, were captive-born (Table 1). The monkeys were maintained in accordance with the "Guide for the Care and Use of Laboratory Animals"11 and the Animal Welfare Act Regulations. Husbandry conditions have been described in detail previously.8

Table 1.

Summary of clinical, gross, and histologic findings in seven Saguinus mystax with pulmonary alveolar proteinosis.

Case
No.
Sex Age Origin Status Time in
Captivity
Clinical/other findings
1 male adult wild-caught VHR 46 m cardiomyopathy, periportal edema, glomerulonephropathy
2 male 70 m captive-born VHR 70 m cardiomyopathy, portal hepatitis with bile duct hyperplasia, glomerulonephropathy, colitis cystica profunda
3 male 72 m captive-born VHR 72 m dyspnea, cardiomyopathy, dissecting aorta, hepatocellular vacuolation with fibrosis, glomerulonephropathy, colitis cystica profunda
4 female adult wild-caught VHR 57 m cardiomyopathy, portal hepatitis with fibrosis and bile duct hyperplasia, glomerulonephropathy, colitis cystica profunda
5 male adult wild-caught naïve 36 m congestive heart failure, hind limb paresis, cardiomyopathy, aortic and iliac artery thrombosis, hepatocellular vacuolation and necrosis, glomerulonephropathy
6 female adult wild-caught naïve 44 m rectal prolapse, monocytosis & basophilia, cardiomyopathy, hepatocellular vacuolation and glomerulonephropathy
7 male adult wild-caught VHR 63 m congestive heart failure, hepatic fibrosis, glomerulopathy, colitis cystica profunda

m = months; VHR = retired from viral hepatitis research (hepatitis A virus and hepatitis GB virus type B).

Histochemistry

Tissues from all major organs were fixed in 10% neutral buffered formalin, embedded in paraffin, sections cut at 5 µm and stained with hematoxylin-eosin (H&E). In addition, lung sections were stained with Masson’s Trichrome, Periodic Acid Schiff (PAS) with and without diastase predigestion, Gram, Alcian Blue (ph 2.5), Elastic Van Gieson, Toluidine Blue, Congo red, and Oil red O.4

Immunohistochemistry

Immunohistochemistry for surfactant proteins A (SP-A), B (SP-B), C (SP-C) and D (SP-D) were performed on formalin-fixed paraffin-embedded lung sections. Briefly, tissues were cut in 5 µm sections and placed on slides. For SP-A, SP-B and SP-D, sections were deparaffinized, dehydrated and heat induced antigen retrieval was performed with Diva Decloaker solution pH 6.2 (Biocare Medical, Concord, CA), 20 min for SP-A and SP-B and 30 min for SP-D. Slides were processed in a DAKO Autostainer (Dako, Carpinteria, CA). For SP-A and SP-B, Background Sniper (Biocare) was applied as a protein block. Slides were incubated for 1 hr at room temperature (RT) with either anti-surfactant protein A antibody (Millipore, Temecula, CA; catalog #ab3420, rabbit polyclonal, species reactivity: human, mouse, rat, primate; dilution 1:500) or surfactant protein B Mature (Abcam, Cambridge, MA; catalog #ab40876, rabbit polyclonal, species reactivity: mouse, sheep, cow, and human; dilution 1:500). Mach 4 Universal AP Polymer (Biocare) was used as detection system, Vulcan Fast Red (Biocare) as chromogen, and CAT hematoxylin (Biocare, dilution 1:1) as counterstain. For Surfactant D, endogenous peroxidase was blocked with Peroxidazed 1 (Biocare); endogenous biotin, with a commercial avidin-biotin blocking kit (Vector Laboratories, Burlingame, CA), and as a protein block 10% mouse serum was used (Jackson ImmunoResearch, West Grove, PA) followed by incubation for 1 hour at RT with a mouse monoclonal biotinylated antibody to surfactant protein D (Abcam, catalog #15695, clone IIE11, species reactivity: human and rat, dilution 1:40). 4plus Streptavidin HRP Label (Biocare) was used as detection system, Vector NovaRED (Vector) as chromogen and Weigert’s Iron hematoxylin (Dilution 1:1, Electron Microscopy Sciences, Hartfield, PA) as counterstain. For Surfactant Protein C, a Leica Bond-Max Automated System (Leica Microsystems, Bannockburn, IL) was used with the Bond Polymer Red Refine Detection Kit (Leica). Slides were placed in the autostainer and subsequent steps were performed by the automated system in the following order: deparaffinization with Bond Dewax Solution (Leica); heat-induced antigen retrieval with Bond Epitope Retrieval Solution 1 (Leica); protein block with Background Sniper (Biocare), incubation with rabbit polyclonal to Surfactant Protein C (SP-C) at RT (Abcam, catalog #28744; species reactivity: human and mouse; dilution 1:100); detection with Polymer AP and Mixed Red Refine, and counterstained with CAT hematoxylin (Biocare, dilution 1:1). Positive and negative controls were run for each sample and each antibody.

Electron Microscopy

For transmission electron microscopy (TEM), formalin-fixed tissues from case #3 and from a normal tamarin lung were transferred to 2.5% glutaraldehyde overnight, then to phosphate buffer 0.1M at 7.2 pH, and to 1% osmium tetroxide. Following fixation, the samples were washed in 0.2M sodium cacodylate, dehydrated through a graded ethanol series, and embedded in epoxy resin (EMBed 812 resin Electron Microscopy Sciences, Hartfield, PA). In two animals (Cases #2 and #3), the areas of interest were trimmed from the paraffin block, washed three times in xylene for 30 min each, changed to 2:1 propylene oxide: EPON, 1:2 propylene oxide: EPON, and embedded in EMBed 812 resin (Electron Microscopy Science). Thin (80 nm) sections were obtained with a ultramicrotome, placed onto 300 mesh copper grids, and stained with saturated uranyl acetate in 50% methanol and then with lead citrate. The grids were viewed in a JEM-1200EXII electron microscope (JEOL Ltd, Tokyo, Japan) at 80kV and images were recorded on a XR611M, mid mounted, 10.5Mpixel, CCD camera (Advanced Microscopy Techniques Corp, Danvers, MA).

Radiography

Thoracic radiographs were available for one animal (Case #6). Images were taken in right lateral and dorso-ventral recumbency with a Fuji x-ray machine (setting kvp 68, mas 75).

Results

Gross lesions were indistinct at necropsy, but noticeable in affected formalin-fixed lung lobes as discrete multifocal areas of discoloration, distributed primarily at the periphery of the lobes, with irregular borders and a cream to light yellow tint (0.2 up to 1 cm3). Some areas bulged slightly from the lung parenchyma and some were contracted and consolidated. Upon microscopic examination, affected areas were characterized by intra-alveolar accumulation of fine to dense granular amphophilic material some presenting a strong eosinophilic rim, foamy alveolar macrophages and ghost cell remnants (Figures 1 and 2). Inflammation of adjacent alveolar septa was not a prominent feature, but the interstitium was occasionally expanded by mild lymphocytic infiltrates. There was multifocal mild to moderate hypertrophy and hyperplasia of type II pneumocytes with variable interstitial fibrosis confirmed by Masson’s trichrome. The intra-alveolar material was PAS positive and diastase resistant (Figure 3). Presence of bacteria (Gram Stain), mast cells (Toluidine Blue), and amyloid (Congo Red) was ruled out. Using Alcian blue (pH 2.5), some intra-alveolar deposits stained a very light blue and some deposits were reactive to the counterstain, Nuclear Fast Red. Oil red O stained the deposits with a reddish hue, indicating a lipid component. All samples had deeply basophilic round lamellar microcalcifications in different stages of development and numbers, placed frequently within alveoli but also within bronchioli, bronchi, and the lipoproteinaceous material.

Figure 1-7.

Figure 1-7

Figure 1. Lung; moustached tamarin, case No.4. Intra-alveolar accumulation of lipoproteinaceous amphophilic material, foamy alveolar macrophages, and ghost cell remnants, with alveolar septal thickening (arrows). H&E.

Figure 2. Lung; moustached tamarin, case No.3. Intra-alveolar amphophilic deposit with strong eosinophilic areas (arrowheads). H&E.

Figure 3. Lung; moustached tamarin, case No.4. Diastase resistant PAS-positive intra-alveolar material with non-staining globular areas, marked pleural and interalveolar septa thickening, and type II pneumocyte hyperplasia and hypertrophy. Periodic Acid Schiff with Diastase Digestion.

Figure 4. Lung; moustached tamarin, case No.3. Surfactant Protein A (1:500). Some aggregates show positive reaction only at the periphery (arrowheads). Immunohistochemistry, Vulcan Fast Red chromogen, Hematoxylin counterstain.

Figure 5. Lung; moustached tamarin, case No.1. Surfactant Protein B (1:500). Strong reaction in intra-alveolar material, some areas at the periphery (arrowheads) and in the center remain unstained. Immunohistochemistry, Vulcan Fast Red chromogen, Hematoxylin counterstain.

Figure 6. Lung; moustached tamarin, case No.6. Surfactant Protein C (1:100). Strong reaction in type II pneumocytes with occasional and partial reaction in intra-alveolar aggregates (arrowhead). Immunohistochemistry, Bond Polymer Red Refine Detection Kit, Hematoxylin counterstain.

Figure 7. Lung; moustached tamarin, case No.4. Surfactant Protein D (1:40). Strong reaction on the periphery of the deposits (arrowheads). Immunohistochemistry, Vector NovaRed chromogen, Weigert’s Iron Hematoxylin counterstain.

There were random foci of emphysema and atelectasis with mildly thickened pleura over affected areas. Pleural infolding was noted in peripheral lesions, associated with contraction and fibrous scarring (Figure 3). Four of the seven animals exhibited discrete foci of osseous metaplasia.

The intra-alveolar deposits reacted strongly to SP-B in all lung samples and it was the most abundant, followed by SP-A (Figures 4 and 5). For both SPs, in some cases either the periphery or the center reacted and the rest remained unstained; free form was noted lining the alveoli, and inside alveolar macrophages and type II pneumocytes. SP-C exhibited a strong reaction in type II pneumocytes but the intra-alveolar material stained weakly (Figure 6). SP-D reactivity was strong but limited to the periphery of the deposits; in type II pneumocytes was very weak (Figure 7).

To establish a reference point in the ultrastructural features, normal lung tissues from a clinically healthy S. mystax (confirmed by light microscopy) were processed with affected animal samples for TEM examination. Compared to normal tamarin lung, the lung lesions in the tamarins were characterized by thickened alveolar septa consisting of large numbers of irregularly arranged collagen fibers, some fibroblasts, few type I pneumocytes and numerous type II pneumocytes. Type II pneumocytes contained increased numbers of osmiophilic lamellar inclusion bodies in the cytoplasm, which were variable in size and staining intensity, abnormally-shaped, and often coalesced (Figure 8). Attenuation of type II pneumocyte surface microvilli and swelling of mitochondria and rough endoplasmic reticulum was observed. The alveolar spaces contained in some areas large numbers of alveolar macrophages free in alveoli and large amorphous dense aggregates consisting of what appeared to be compacted surfactant and cellular debris. The alveolar macrophages were swollen and had numerous phagolysosomes containing amorphous rounded bodies or lamellar structures resembling type II pneumocyte lamellar inclusion bodies. These most likely represented ingested surfactant. TEM examination did not reveal a possible etiologic agent.

Figure 8.

Figure 8

Lung; moustached tamarin, case No.3. Type II pneumocytes showing varied-sized, abnormally shaped, coalescing, lamellar inclusion bodies. Note capillary in center of the image. Transmission electron microscopy, uranyl acetate and lead citrate.

Thoracic radiographs available from one animal (case #6) showed randomly distributed small, patchy, radiopaque areas in the lungs (Figure 9).

Figure 9.

Figure 9

Lung; moustached tamarin, case No.6. Left lateral thoracic radiograph showing discrete radio-opaque areas on cranial and diaphragmatic lung lobes (arrowheads). Radiograph.

Discussion

Human PAP was originally classified in three clinical forms: 1) idiopathic, acquired or primary, 2) secondary, and 3) congenital.13,17,21,25 However it is more aptly described as a clinical syndrome caused by a heterogeneous group of disorders.10,22 More than 90% of all cases of PAP are classified as a primary acquired disorder of unknown etiology.7,14,21,26 Recently, investigators have proposed to classify the idiopathic form as autoimmune due to the finding of increased serum values of autoantibodies against granulocyte macrophage-colony stimulating factor (GM-CSF).3,13,21,25 GM-CSF, is a potent stimulator of myeloid hematopoiesis,13 and is necessary for the terminal differentiation and function of alveolar macrophages,3,23 which are responsible for clearance of surfactant from alveoli.13,21,25

Secondary PAP develops associated with conditions such as immune deficiency syndromes, chronic inflammation, hematologic malignancies, pharmacologic immune suppression, inhalation of inorganic dust or toxic fumes, and some chronic infections and represents 5 to 10% of cases.3,7,10,25 It was believed that the mechanism of development of secondary PAP was unrelated to autoantibodies against GM-CSF but recently two cases were reported in which people had elevated titers of autoantibodies against GM-CSF after exposure to industrial dust inhalation.5,14

Congenital PAP is very rare, representing approximately 2 % of cases. The disease manifests in the neonatal period an has very poor prognosis.7 It is caused by rare gene mutations that include SP-B deficiency/mutation; SP-C mutations, granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor β or α chain abnormalities, and ATP-binding cassette transporter A3 (ABCA3) gene mutations.3,10,13,22

We were unable to identify the trigger for development of PAP in the moustached tamarins. We hypothesized that experimental viral hepatitis might be related to the pathogenesis of PAP, since five of 15 animals enrolled in such studies presented with the lesions. An environmental factor was also considered as a possible cause due to the high incidence (33.33%) of PAP in these 15 animals; thus secondary PAP was postulated and a genetic component considered (captive-born twins developed the disease). Finding two out nine research-naïve animals (22.22%) with PAP housed in a different location downplayed the importance of the virus as an etiologic factor and encourages consideration of a secondary origin.

Although acquired or immune-mediated PAP represents 90% of all reported human cases,7,13,21 the incidence of this clinical form has been estimated to be 3.7 per million of population.12 In experiments in which the secondary clinical form is induced, following exposure to a noxa that impairs the function of alveolar macrophages, the accumulation of varying amounts of surfactant is present in all exposed animals, this supports our hypothesis of secondary PAP in tamarins.10,24

The clinical manifestations of the disease in humans are nonspecific respiratory symptoms including dyspnea, cough, chest pain, fatigue, and weight loss, and in some cases, low-grade fever.13,22 None of these signs were noted in the tamarins included in this report except in case #3, which had an annotation in its medical record of abnormal breathing and nasal discharge 3 years prior to its death (Table 1). However, this symptom is nonspecific and accompanies many respiratory diseases.16 A male preponderance in developing PAP has been suggested in the literature.7,12,13,19,21,22 We can not assert this in tamarins due to the small number of cases we studied. However, it is worth noting that five males and two females were affected.

Case #6 presented monocytosis and basophilia, both may be present in certain myeloproliferative disorders,15 listed as cause for secondary PAP,3,10,12 even though this animal wasn’t evaluated in order to confirm or discard such affection, we consider this a noteworthy fact.

We followed the work of Rosen and collaborators in confirming the nature of the material in alveoli.19 Masson’s Trichrome and Elastic Van Gieson stains demonstrated mild to marked multifocal interalveolar septal thickening due to collagen deposition. Periodic Acid-Schiff stain, revealed the amorphous alveolar material as intensely positive and resistant to diastase digestion, though globular areas were unreactive (Figure 3), resembling what has been reported in the literature.10 With Alcian Blue (pH 2.5) the reaction was a very pale light blue, indicating a low amount of carboxylated and sulfated acid mucopolysaccharides and glycoproteins.4

Marked interstitial fibrosis, also observed in humans with PAP,9,13,19,22 was present in two tamarins (cases #2 and #4). Lung fibrosis has been described in rodents exposed experimentally to silica dust to produce secondary PAP.9 Cholesterol crystal clefts within the eosinophilic material in the alveoli have been occasionally reported in humans, this was not observed in the tamarins.5,7

In normal lungs, a thin layer of surfactant lines the alveolar surface and reduces surface tension, preventing collapse of the lung. In humans, surfactant is composed by lipids (90–95%) and (5–10%) proteins (SP-A, SP-B, SP-C and SP-D).12,18 SP-A and SP-D are large hydrophilic collectin proteins involved in host defense, whereas SP-B and SP-C have a small molecular weight, are hydrophobic and involved in maintaining the surface tension in the air-liquid interface.18 In human PAP, the accumulation of surfactant has been shown to be due to lack of clearance of all four SPs and precursors of SP-B by alveolar macrophages, and to an abnormal secretion of transport vesicles containing precursors of SP-B.2 The dynamics of the interaction among the different SPs and their role in human PAP has been reviewed in the literature extensively.1,2,3,18

For immunohistochemical identification of the four SPs, titration runs were performed using tamarin lung tissue processed under optimal circumstances, within 48–72 hours post fixation in 10% neutral buffered formalin (NBF), type II pneumocytes and alveolar macrophages in control tissues were positive for all SPs. Affected animal samples were not kept in 10% NBF under optimal conditions but we obtained consistent staining of the lipoproteinaceous material, this wasn’t the case for type II pneumocytes and alveolar macrophages, in which the staining was either strong, weak or absent. Since ours wasn’t a controlled study, we cannot interpret the staining reactivity in these cells. Based on our observations, SPs contained within the accumulated surfactant withstands long fixation time (≥ 1 year) in 10% NBF.

Upon immunohistochemical examination, the strong eosinophilic areas present in some of the lipoproteinaceous aggregates (Figure 2) reacted strongly against SP-D (Figure 7). There are two reports of similar findings in humans, in which the intensely eosinophilic coarse granules within the fine granular substance in the alveolar spaces reacted positively to SP-D and were negative to SP-A and KL-6, a mucin-like glycoprotein that is expressed in type II pneumocytes.14,17

Ultrastructural analysis of tamarin lungs by TEM were consistent with previous reports in humans with PAP where the lesions are characterized by amorphous electron dense material in alveolar spaces and alveolar wall thickening due to increased amounts of collagen and type II pneumocyte hypertrophy and hyperplasia with numerous cytoplasmic osmiophilic lamellar bodies, some irregularly-shaped.22 Intraalveolar macrophages were enlarged containing numerous phagolysosomes with irregularly-shaped and varied-sized osmiophilic lamellar bodies resembling ingested surfactant.

The pattern of opacities observed in case #6 thoracic radiographs were nonspecific. Radiographic findings in PAP have been described as ground glass opacities and areas of consolidation in the lungs, but this pattern of diffuse lung disease is not exclusive and is seen in other conditions.7,10,12,16

Animal models include mice deficient in GM-CSF, which develop lung lesions similar to PAP in humans.6,23 A notable difference is the extensive lymphoid hyperplasia, predominantly B cells, around lung airways and blood vessels. This characteristic hasn’t been described in humans, and we didn’t find this in tamarins either. Recently PAP has been experimentally reproduced in Cynomolgus monkeys by intravenous injection of patient derived GM-CSF autoantibodies after immunosuppression with Rituximab and Cyclophosphamide.20 Other experimental animal models include rodents in which lesions similar to PAP were reproduced by inhalation of inorganic dusts.5,24

Additional lesions noted on microscopic examination in these animals were colitis cystica profunda (four of five, gastrointestinal tract of two animals were unavailable), cardiac hypertrophy and fibrosis (seven of seven), and chronic nephropathy (six of seven). Mild to moderate subintimal thickening of pulmonary arteries concomitant with heart disease were present in four animals. One animal (Case #4) had a pentastomid nymph in the lung.

Major advances in understanding the pathogenesis of human PAP have been achieved in recent years. However, basic questions remain about its pathophysiology and the extent to which environment and genetics play as factors in the disease. Based on our observations, and the similarities of human and tamarin PAP, Saguinus mystax could be a suitable animal model for the study of this disease. To our knowledge, there are no reports of spontaneous PAP in animals.

Acknowledgments

This study was supported by the Intramural Research Program of the National Institutes of Health, National Institute of Allergy and Infectious Diseases (NIAID), Comparative Medicine Branch, the Office of Research Services, and a NIAID contract to SoBran Inc. We thank Dr. Robert Purcell and Dr. Sue Emerson for kindly letting us use tamarin tissue samples from their previous studies; and Dr. Richard Herbert for providing S. mystax radiographs and tissue samples.

References

  • 1.Andreeva AV, Kutuzov MA, Voyno-Yasenetskaya TA. Regulation of surfactant secretion in alveolar type II cells. Am J Physiol Lung Cell Mol Physiol. 2007;293(2):L259–L271. doi: 10.1152/ajplung.00112.2007. [DOI] [PubMed] [Google Scholar]
  • 2.Brasch F, Birzele J, Ochs M, et al. Surfactant proteins in pulmonary alveolar proteinosis in adults. Eur Respir J. 2004;24(3):426–435. doi: 10.1183/09031936.04.00076403. [DOI] [PubMed] [Google Scholar]
  • 3.Carey B, Trapnell BC. The molecular basis of pulmonary alveolar proteinosis. Clin Immunol. 2010;135(2):223–235. doi: 10.1016/j.clim.2010.02.017. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Carson FL, Hladik C. Histotechnology: A Self-Instructional Text. 3rd. Chicago, IL: American Society for Clinical Pathology Press; 2009. [Google Scholar]
  • 5.Cummings KJ, Donat WE, Ettensohn DB, et al. Pulmonary alveolar proteinosis in workers at an indium processing facility. Am J Respir Crit Care Med. 2010;181(5):458–464. doi: 10.1164/rccm.200907-1022CR. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Dranoff G, Crawford AD, Sadelain M, et al. Involvement of granulocyte-macrophage colony-stimulating factor in pulmonary homeostasis. Science. 1994;264(5159):713–716. doi: 10.1126/science.8171324. [DOI] [PubMed] [Google Scholar]
  • 7.Frazier AA, Franks TJ, Cooke EO, et al. From the archives of the AFIP: pulmonary alveolar proteinosis. Radiographics. 2008;28(3):883–899. doi: 10.1148/rg.283075219. [DOI] [PubMed] [Google Scholar]
  • 8.Gozalo A, Cheng L, St. Claire M, et al. Pathology of Captive Moustached Tamarins (Saguinus mystax) Comp Med. 2008;58(2):188–195. [PMC free article] [PubMed] [Google Scholar]
  • 9.Hudson AR, Halprin GM, Miller JA, et al. Pulmonary interstitial fibrosis following alveolar proteinosis. Chest. 1974;65(6):700–702. doi: 10.1378/chest.65.6.700. [DOI] [PubMed] [Google Scholar]
  • 10.Huizar I, Kavuru MS. Alveolar proteinosis syndrome: pathogenesis, diagnosis, and management. Curr Opin Pulm Med. 2009;15(5):491–498. doi: 10.1097/MCP.0b013e32832ea51c. [DOI] [PubMed] [Google Scholar]
  • 11.Institute for Laboratory Animal Research, National Research Council. Guide for the care and use of laboratory animals. Washington, DC: National Academy Press; 1996. [Google Scholar]
  • 12.Ioachimescu OC, Kavuru MS. Pulmonary alveolar proteinosis. Chron Respir Dis. 2006;3(3):149–159. doi: 10.1191/1479972306cd101rs. [DOI] [PubMed] [Google Scholar]
  • 13.Juvet SC, Hwang D, Waddell TK, et al. Rare lung disease II: pulmonary alveolar proteinosis. Can Respir J. 2008;15(4):203–210. doi: 10.1155/2008/528948. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Kobayashi M, Takeuchi T, Ohtsuki Y. Differences in the immunolocalization of surfactant protein (SP)-A, SP-D, and KL-6 in pulmonary alveolar proteinosis. Pathol Int. 2008;58(3):203–207. doi: 10.1111/j.1440-1827.2007.02212.x. [DOI] [PubMed] [Google Scholar]
  • 15.Latimer KS, Mahaffey EA, Prasse KW. Clinical Pathology. 4th. Ames, IA: Iowa State Press; 2003. [Google Scholar]
  • 16.Leslie KO. My approach to interstitial lung disease using clinical, radiological and histopathological patterns. J Clin Pathol. 2009;62(5):387–401. doi: 10.1136/jcp.2008.059782. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Ohtsuki Y, Kobayashi M, Yoshida S, et al. Immunohistochemical localisation of surfactant proteins A and D, and KL-6 in pulmonary alveolar proteinosis. Pathology. 2008;40(5):536–539. doi: 10.1080/00313020802198077. [DOI] [PubMed] [Google Scholar]
  • 18.Orgeig S, Hiemstra PS, Veldhuizen EJ, et al. Recent advances in alveolar biology: Evolution and function of alveolar proteins. Respir Physiol Neurobiol. 2010;173(Suppl):S43–S54. doi: 10.1016/j.resp.2010.04.023. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Rosen SH, Castleman B, Liebow AA. Pulmonary alveolar proteinosis. N Engl J Med. 1958;258(23):1123–1142. doi: 10.1056/NEJM195806052582301. [DOI] [PubMed] [Google Scholar]
  • 20.Sakagami T, Beck D, Uchida K, et al. Patient-derived granulocyte/macrophage colony-stimulating factor autoantibodies reproduce pulmonary alveolar proteinosis in nonhuman primates. Am J Respir Crit Care Med. 2010;182(1):49–61. doi: 10.1164/rccm.201001-0008OC. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Seymour JF, Presneill JJ. Pulmonary alveolar proteinosis: progress in the first 44 years. Am J Respir Crit Care Med. 2002;166(2):215–235. doi: 10.1164/rccm.2109105. [DOI] [PubMed] [Google Scholar]
  • 22.Shah PL, Hansell D, Lawson PR, et al. Pulmonary alveolar proteinosis: clinical aspects and current concepts on pathogenesis. Thorax. 2000;55(1):67–77. doi: 10.1136/thorax.55.1.67. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Stanley E, Lieschke GJ, Grail D, et al. Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology. Proc Natl Acad Sci U S A. 1994;91(12):5592–5596. doi: 10.1073/pnas.91.12.5592. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Toya T, Takata A, Otaki N, et al. Pulmonary toxicity induced by intratracheal instillation of coarse and fine particles of cerium dioxide in male rats. Ind Health. 2010;48(1):3–11. doi: 10.2486/indhealth.48.3. [DOI] [PubMed] [Google Scholar]
  • 25.Trapnell BC, Whitsett JA, Nakata K. Pulmonary alveolar proteinosis. N Engl J Med. 2003;349(26):2527–2539. doi: 10.1056/NEJMra023226. [DOI] [PubMed] [Google Scholar]
  • 26.Xu Z, Jing J, Wang H, Xu F, Wang J. Pulmonary alveolar proteinosis in China: a systematic review of 241 cases. Respirology. 2009;14(5):761–766. doi: 10.1111/j.1440-1843.2009.01539.x. [DOI] [PubMed] [Google Scholar]

RESOURCES